# Royalty Pharma plc (RPRX) FY2024 Q1 Balance Sheet

- Company: Royalty Pharma plc (RPRX)
- Period: As of 2024-03-31
- Filing: Q1 FY2024 10-Q, filed 2024-05-09, accession number 0001802768-24-000021
- Page: https://plicit.ai/financials/rprx/fy2024-q1-balance-sheet
- Chart image: https://plicit.ai/charts/rprx-fy2024-q1-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2024-03-31. The chart shows assets, liabilities and equity at that date.

- **Assets**: 16,130,886,000 US dollars
- **Current assets**: 1,559,719,000 US dollars
- **Non-current assets**: 14,571,167,000 US dollars
- **Liabilities**: 6,267,170,000 US dollars
- **Current liabilities**: 124,574,000 US dollars
- **Non-current liabilities**: 6,142,596,000 US dollars
- **Equity**: 9,863,716,000 US dollars
- **Noncontrolling interest**: 3,363,965,000 US dollars. Included in consolidated equity; this amount is not added again.
- **Cash and cash equivalents**: 843,000,000 US dollars
- **Financial royalty assets**: 660,482,000 US dollars
- **Available for sale debt securities**: 29,000,000 US dollars
- **Other royalty income receivable**: 22,227,000 US dollars
- **Other current assets**: 5,010,000 US dollars
- **Financial royalty assets, net**: 13,465,407,000 US dollars
- **Available for sale debt securities**: 473,700,000 US dollars
- **Equity method investments**: 350,355,000 US dollars
- **Equity securities**: 277,217,000 US dollars
- **Other assets**: 4,488,000 US dollars
- **Distributions payable to legacy non-controlling interests**: 91,409,000 US dollars
- **Interest payable**: 12,595,000 US dollars
- **Accounts payable and accrued expenses**: 11,551,000 US dollars
- **Other current liabilities**: 9,019,000 US dollars
- **Long-term debt**: 6,139,376,000 US dollars
- **Other liabilities**: 3,220,000 US dollars
- **Additional paid-in capital**: 4,074,849,000 US dollars
- **Retained earnings**: 2,427,448,000 US dollars
- **Common stock - Class R Redeemable Shares**: 63,000 US dollars
- **Common stock - Class A Ordinary Shares**: 45,000 US dollars
- **Common stock - Class B Ordinary Shares**: 0 US dollars
- **Deferred shares, $0.000001 par value; issued and outstanding: 2024–388,927 and 2023–384,640**: 0 US dollars
- **Non-controlling interests**: 3,363,965,000 US dollars
- **Treasury interests**: negative 2,654,000 US dollars
- **Gross equity (calculated)**: 9,866,370,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.